NEW YORK (GenomeWeb News) – Maxygen has received a $3.4 million grant from the US Department of Defense to develop its genetic reshuffling technology through a collaboration with the DNA-based vaccine services provider Aldevron, the company said today.
The firm’s ParallelaVax system is used for rapid, high-throughput screening of vaccine candidates in animals.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.